Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

BELLUS Health Inc BLUSD


Primary Symbol: T.BLU

BELLUS Health Inc. is a clinical-stage biopharmaceutical company developing therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. The Company's lead product candidate, BLU-5937, which is a selective, small molecule antagonist of the P2X3 receptor, as an oral therapy to reduce cough frequency in RCC patients. The Company has completed the BLUEPRINT clinical trial, a Phase II trial evaluating BLU-5937 in patients with chronic pruritus associated with AD. The Company is focused on initiating Phase III program. The Company is exploring the use of BLU-5937 in other patient populations experiencing cough hypersensitivity as well as other P2X3-related hypersensitization conditions.


TSX:BLU - Post by User

Bullboard Posts
Comment by webpiloton Dec 23, 2010 8:31am
353 Views
Post# 17887215

RE: A few questions...

RE: A few questions...Recently Vivimind was granted a product number by Health Canada which allows the company to sell the product in a traditional manner and advertise in all media.  Before the number was granted, Vivimind could not advertise on TV, radio, etc.  Now that they can, they will be able to arrange for partnerships. 

Please note that after December 31, 2010 Vivimind will not be available for sale over the Internet.  This decision was just recently made and goes along with the strategy of partnerships, I am sure that any new partnerships do not want to be in competition with Internet sales directly from Ovos.  The fact that all Internet sales will be completely halted very shortly indicates to me that major new partnerships have been arranged (my guess).  Also, the shelf-life of the Vivimind that is currently being sold is April 2011.  I am sure that the company wants product available to it's long standing customer base and will not leave these people hanging thus further re-enforcing the idea that everything is in place with partnerships.

With permission being granted by Canada, Italy, and Spain, can approval for sale in the US be far behind?  The US is being stubborn.  Why do they deny access to a product that has such an important, positive effect on the brain be denied to millions?
Bullboard Posts